司妥昔单抗治疗嵌合抗原受体T细胞治疗相关细胞因子释放综合征与免疫效应细胞相关神经毒性综合征:一项多中心回顾性分析
这项多中心回顾性分析纳入6个学术中心54例CAR-T治疗后发生CRS或ICANS的患者,评估司妥昔单抗的疗效。司妥昔单抗治疗时75%的CRS患者分级改善,60%的ICANS患者分级改善。作者认为司妥昔单抗对CRS和ICANS似乎有效,包括既往已治疗过的毒性,并支持未来开展前瞻性研究。
要点
- 54例CAR-T后CRS/ICANS患者接受司妥昔单抗治疗,其中16例CRS曾用托珠单抗、17例ICANS曾用激素。
- 司妥昔单抗治疗时75%的CRS患者分级改善,60%的ICANS患者分级改善。
- 作者认为司妥昔单抗对CRS和ICANS似乎有效,包括既往已治疗过的毒性。
核心结论
- 司妥昔单抗对CAR-T治疗后的CRS和ICANS似乎有效,包括既往已治疗过的毒性。
- 这些数据支持在CRS和ICANS中使用司妥昔单抗,并为未来前瞻性研究提供依据。
研究设计与样本
- 多中心回顾性分析,纳入来自6个学术中心的真实世界队列。
- 共评估54例CAR-T治疗后接受司妥昔单抗治疗CRS和/或ICANS的患者。
- 16例CRS患者既往接受过托珠单抗治疗,17例ICANS患者既往接受过激素治疗。
主要发现
- 司妥昔单抗治疗时存在的CRS患者中,75%的患者CRS分级改善。
- 司妥昔单抗治疗时存在的ICANS患者中,60%的患者ICANS分级改善。
- 据作者所知,这是CAR-T治疗后因CRS和/或ICANS接受司妥昔单抗治疗的最大队列。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T-cell (CAR-T) therapies are effective in many hematologic malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can affect a significant number of patients. Those who develop refractory CRS or ICANS have few treatment options. Siltuximab, a monoclonal antibody binding circulating interleukin-6, has been proposed to have clinical activity in both CRS and ICANS. We conducted a multicenter retrospective analysis of siltuximab treatment for CRS and ICANS after CAR-T therapy in a real-world cohort from 6 academic centers. Fifty-four patients were evaluated. Sixteen patients had CRS previously treated with tocilizumab and 17 patients had ICANS previously treated with steroids. Of the patients with CRS at the time of siltuximab, 75% had improvement in CRS grade. Of the patients with ICANS at the time of siltuximab, 60% had improvement in ICANS grade. To our knowledge, this is the largest cohort of patients treated with siltuximab for CRS and/or ICANS after CAR-T therapies. Siltuximab appeared to be effective for both CRS and ICANS, including previously treated toxicities. These data support the use of siltuximab in CRS and ICANS as well as provide rationale for future prospective studies.
引用
- Bajwa A, Zhao Q, Geer M, et al. Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis. Blood Adv. 2025. PMID: 39437770. doi:10.1182/bloodadvances.2024013688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。